VRDN - Company ID 0001590750
Viridian Therapeutics, Inc.DE (VRDN) reported net income of -$342.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$342.60M | -26.9% |
| FY 2024 | -$269.90M | -13.5% |
| FY 2023 | -$237.70M | -83.0% |
| FY 2022 | -$129.90M | -63.6% |
| FY 2021 | -$79.40M | +28.3% |
| FY 2020 | -$110.72M | -164.4% |
| FY 2019 | -$41.87M | -28.0% |
| FY 2018 | -$32.70M | -23.4% |
| FY 2017 |
Viridian Therapeutics, Inc.DE (VRDN) reported net income of -$342.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, Viridian Therapeutics, Inc.DE's net income declined from -$2.16M to -$342.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$26.51M |
| -53.5% |
| FY 2016 | -$17.27M | -52.5% |
| FY 2015 | -$11.33M | -43.6% |
| FY 2014 | -$7.89M | -265.3% |
| FY 2013 | -$2.16M | - |